Corcept Therapeutics Incorporated Common Stock (CORT)

FairStock Score: 30/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at Corcept, I see a commercial-stage biopharma selling Korlym for Cushing's syndrome. Revenue has grown from $482.4M in fiscal year 2023 (the year ended 2023-12-31), to $675.0M in fiscal year 2024 (the year ended 2024-12-31), to $761.4M in fiscal year 2025 (the year ended 2025-12-31). But profits have not marched in step: net income was $106.1M, then $141.2M, then $99.7M over those same years. In fiscal Q1 2026, the quarter ended 2026-03-31, it reported a net loss of $31.8M; in fiscal Q2 2026, the quarter ended 2026-06-30, net income rebounded to $43.0M on $256.1M of revenue. The balance sheet is conservative — FairStock calculations show debt/equity of 0.01, Piotroski F-Score 7/9, and Altman Z-Score 43.63. But returns are modest: ROE 8.23%, ROCE 0.47%, and trailing-twelve-month free cash flow of $106.9M gives only a 0.8% FCF yield at the 2026-10-13 close. Valuation is the rub. FairStock calculations show a P/E of 261.78, P/B of 18.01, PEG of 11.74, EV/EBITDA of 1431.43, Graham Number of $8.14 against a $117.80 price, and a margin of safety of -1347.17%. The FairStock score is 30/100, and its Lynch category is SLOW GROWER — Shrinking: profit -1.2% a year over five years, revenue 16.6%. A beta of 0.45 and no dividend are not enough to offset the price. Biotech can be wonderful when a drug franchise compounds, but I demand predictability and a margin of safety. Here revenue is rising, yet profit is uneven and the price already assumes a very bright future. That looks more like speculation than investment.

In plain English: Corcept Therapeutics makes and sells a medicine called Korlym for Cushing's syndrome, a hormone-related condition, and is developing other medicines. Sales are growing, but profits have been uneven, with a loss in early 2026 and a profit in the next quarter. At the recent price, the shares look very expensive compared with the company's recent earnings and net worth.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer